IP Library Granted Patent US 9,060,976
Granted Patent B2
US 9,060,976 · App. 13/726,324 · Granted Jun 23, 2015

Pharmaceutical formulation containing gelling agent

Inventors: Curtis Wright (Rockport, MA); Benjamin Oshlack (Boca Raton, FL); Christopher Breder (Greenwich, CT)
Assignees: Purdue Pharma L.P.; The P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.
A61K31/167A61K9/2013A61K9/205A61K9/2054A61K9/0002A61K31/439A61K31/485A61K47/38A61K47/36A61K47/10A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,060,976
App. No.
13/726,324
Granted
Jun 23, 2015
Kind
B2
Abstract

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Claims (8)

1. An extended release abuse deterrent dosage form comprising:

a. a core matrix comprising a blended mixture of:

(a) PEO having a molecular weight of from about 300,000 daltons to about 5,000,000 daltons;

(b) magnesium stearate; and

(c) oxycodone or a pharmaceutically acceptable salt thereof;

wherein the core matrix is heated to melt at least a portion of the PEO included in the core matrix during preparation of the dosage form; and

b. PEG applied onto the core matrix;

wherein the dosage form provides extended release of the drug.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2019
From: THE P.F. LABORATORIES, INC.; PURDUE PHARMA TECHNOLOGIES, INC.
To: PURDUE PHARMA L.P.
Reel/Frame 048932/0651 →
Continuity (5)
Continuation 13349449 · Jan 12, 2012
Continuation 12653115 · Dec 8, 2009
Continuation 10214412 · Aug 6, 2002
Provisional Application 60310534 · Aug 6, 2001
Related Publication 20130217716A1 · Aug 22, 2013